

**FORMATO EUROPEO
PER IL CURRICULUM
VITAE**



INFORMAZIONI PERSONALI

Nome SPUGNINI ENRICO PIERLUIGI
Indirizzo
Telefono
Fax
E-mail

Nazionalità

Data di nascita

ISTRUZIONE E FORMAZIONE

- 2020
- Nome e tipo di istituto di istruzione o formazione Ministero dell'Università e della Ricerca
 - Principali materie / abilità professionali oggetto dello studio Settore concorsuale 07-H4 "Clinica Medica e Farmacologia Veterinaria
 - Qualifica conseguita Abilitazione Scientifica per Professore fascia II
 - Livello nella classificazione nazionale (se pertinente)
- 2006
- Nome e tipo di istituto di istruzione o formazione Diplomato presso l'European College of Internal Medicine, Companion Animals, Specialty of Oncology
 - Principali materie / abilità professionali oggetto dello studio European College of Veterinary Internal Medicine, Companion Animals, Specialty of Oncology
 - Qualifica conseguita Oncologia veterinaria
 - Livello nella classificazione nazionale (se pertinente) Diplomato
- 2006
- Nome e tipo di istituto di istruzione o formazione Diplomato presso l'American College of Internal Medicine, Specialty of Oncology
 - Principali materie / abilità professionali oggetto dello studio American College of Internal Medicine, Specialty of Oncology
 - Qualifica conseguita Oncologia Veterinaria, medicina traslazionale
 - Livello nella classificazione nazionale (se pertinente) Diplomato
- 2004-2006
- Nome e tipo di istituto di istruzione o formazione Ph D program
 - Principali materie / abilità professionali oggetto dello studio Bulgarian Academy of Sciences, Institute of Experimental Pathology and Parasitology
 - Qualifica conseguita Elettrochemioterapia, oncologia veterinaria, medicina traslazionale
 - Livello nella classificazione nazionale (se pertinente) Dottore di Ricerca

- 1992-1994
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)
- 1986-1992
 - Nome e tipo di istituto di istruzione o formazione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
 - Livello nella classificazione nazionale (se pertinente)

Scuola di Specializzazione in Oncologia Veterinaria
North Carolina State University, 4700 Hillsborough Street, Raleigh, NC 27606, U.S.A.

Oncologia Veterinaria, chemioterapia, radioterapia ed ipertermia veterinaria.

Specialista in oncologia veterinaria

Corso di Laurea in Medicina Veterinaria
Facoltà di Medicina Veterinaria, Università degli studi di Perugia, Perugia, Italia

Laureato in Medicina Veterinaria

BORSE DI STUDIO

- Date (da – a)
- Nome e tipo di istituto di istruzione o formazione
- Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita
- Livello nella classificazione nazionale (se pertinente)

[Iniziare con le informazioni più recenti ed elencare separatamente ciascun corso pertinente frequentato con successo.]

ESPERIENZA LAVORATIVA- PROFESSIONALE

- Gennaio 1997-ad oggi
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Gennaio 1997-30-09-2021
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Gennaio 1999-Marzo 2001
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego

Oncologo Veterinario Libero Professionista

Libera professione
Oncologo

Consulente Oncologico Veterinario e Responsabile del benessere animale
Istituto Regina Elena- via delle messi d'oro 156-00158 Roma

IRCS
Consulente e ricercatore a contratto
Responsabile del benessere animale

Consulente Veterinario e Responsabile del Benessere Animale
C.N.R. Viale Marx 186, Roma, Italia

Consulente

- Principali mansioni e responsabilità

Responsabile del benessere animale

ATTIVITÀ SCIENTIFICA

- Nome e indirizzo del datore di lavoro

Gennaio 1997-ad oggi

Consulente di ricerca a contratto

Istituto Regina Elena- via delle messi d'oro 156-00158 Roma

ELENCO DELLE PUBBLICAZIONI

1. **Spugnini EP**, Donald E. Thrall, G. Sylvester Price , Nicholas J. Sharp, Karen Munana , Rodney L. Page . Primary irradiation of canine intracranial masses. Vet Radiol Ultras. 2000; 41: 377-80.
2. **Spugnini EP**, A Bartolazzi, D Ruslander. Seminoma with cutaneous metastases in a dog. J Am An Hosp Assoc . 2000; 36: 253-6.
3. **Spugnini EP**, D Ruslander, A Bartolazzi. Extraskelatal osteosarcoma in a cat. J Am Vet Med Assoc 2001; 219: 60-62.
4. **Spugnini EP**. Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. J Am Vet Med Assoc 2002; 221: 1437-1440.
5. **Spugnini EP**, A Porrello. Potentiation of chemotherapy in companion animals with spontaneous large neoplasms by application of biphasic electric pulses. J. Exp. Clin. Canc. Res. 2003; 22: 571-580.
6. Porrello A, Cardelli P, **Spugnini EP**. Pet models in cancer research: general principles. J. Exp. Clin. Canc. Res. 2004; 23, 2: 5-17.
7. **Spugnini EP**, Citro G, Porrello A. Rational design of new electrodes for electrochemotherapy. J. Exp. Clin. Canc. Res 2005; 24: 245-254.
8. Cardillo I, **Spugnini EP**, Verdina A, Galati R, Citro G, Baldi A. Cox and mesothelioma: an overview. Histol Histopathol. 2005; 20: 1267-1274.
9. **Spugnini EP**, Porrello A, Citro G, Baldi A. Cox-2 overexpression in canine tumors: potential therapeutic targets in oncology. Histol Histopathol. 2005; 20: 1309-1312.
10. Campioni M, Santini D, Tonini G, Murace R, Dragonetti E, **Spugnini EP**, Baldi A. Role of APAF-1, a key regulator of apoptosis, in melanoma progression and chemoresistance. Exp Dermatol. 2005; 14: 811-818.

11. **Spugnini EP**, Dragonetti E, Murace R, Esposito V, Groeger AM, Baldi A. A spontaneous model of intestinal melanoma in dogs. In Vivo, 19: 1051-1054, 2005.
12. Porrello A, Cardelli P, **Spugnini EP**. Oncology of companion animals as a model for humans: an overview of tumor histotypes. J Exp Clin Cancer Res. 2006; 25: 97-106.
13. **Spugnini EP**, Esposito V, Groeger AM, Cassandro R, Chirianni A, Baldi A. Effects of Indinavir in a preliminary phase I study on dogs with stage III splenic hemangiosarcoma. In Vivo. 20: 125-128, 2006.
14. Esposito V, Palescandalo E, **Spugnini EP**, Montesarchio V, De Luca A, Cortese G, Baldi A, Chirianni A. Evaluation of antitumor properties of indinavir in a murine model of epatocarcinoma. Clin Cancer Res. 2006; 12 : 2634-2639.
15. **Spugnini EP**, Dragonetti E, Vincenzi B, Onori E, Citro G, Baldi A. Pulse mediated chemotherapy enhances local control and survival in a spontaneous canine mucosal melanoma model. Melanoma Res. 2006; 16: 23-27.
16. **Spugnini EP**, Baldi A, Vincenzi B, Bongiorno F, Bellelli C, Citro G, Porrello A. Intraoperative versus postoperative electrochemotherapy in soft tissue sarcomas: a preliminary study in a spontaneous feline model. Cancer Chemother Pharmacol. 2007; 59 (3): 375-381.
17. Baldi A, Colloca E, **Spugnini EP**. Lomustine for the treatment of gastrointestinal mast cell tumor in a dog. J Sm Anim Pract 2006; 47: 465-467.
18. Baldi A, **Spugnini EP**. Thoracic hemangiopericytoma in a cat. Vet Rec 2006; 159: 598-599.
19. **Spugnini EP**, Bosari S, Citro G, Cognetti F, Baldi A. Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression. Int J Biochem Cell Biol 2006; 38: 2000-2004.
20. **Spugnini EP**, Cardillo I, Verdina A, Crispi S, Saviozzi S, Calogero R, Nebbioso A, Altucci L, Cortese G, Galati R, Chien J, Shridhar V, Vincenzi B, Citro G, Cognetti F, Sacchi A, Baldi A. Piroxicam inhibits the growth of mesothelioma cells and enhances platinum based chemotherapy in a mouse xenograft model of peritoneal mesothelioma. Clin Cancer Res 2006; 12: 6133-6143.
21. Esposito V, Campioni M, De Luca A, **Spugnini EP**, Baldi F, Cassandro R, Mancini A, Vincenzi B, Groeger A, Caputi M, Baldi A. Analysis of HTRA1 serine protease expression in human lung cancer. Anticancer Res. 2006; 26(5A): 3455-3459.

22. **Spugnini EP**, Vincenzi B, Baldi F, Citro G, Baldi A. Adjuvant electrochemotherapy for the treatment of incompletely resected canine mast cell tumors. Anticancer Res. 2006; 26(6B) 4585-4889.
23. **Spugnini EP**, Vincenzi B, Citro G, Santini D, Dotsinsky I, Mudrov N, Montesarchio V, Laieta MT, Esposito V, Baldi A . Adjuvant electrochemotherapy for the treatment of incompletely excised spontaneous canine sarcomas. In Vivo 2007; 21: 819-822.
24. **Spugnini EP**, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Baroni A, Ruocco E, Lieta MT, Montesarchio V, Cassandro R, Citro G, Baldi A. Local control and distant metastases after electrochemotherapy of a canine anal melanoma. In Vivo 2007; 21: 897-900.
25. **Spugnini EP**, Citro G, Mellone P, Dotsinsky I, Mudrov N, Baldi A. Electrochemotherapy for localized lymphoma: a preliminary study in companion animals. J Exp Clin Cancer Res 2007; 26: 343-346.
26. **Spugnini EP**, Baldi F, Mellone P, Feroce F, Bonetto F, Citro G, Baldi A. Patterns of tumor responses in canine and feline cancer patients treated with electrochemotherapy. J Transl Med. 2007; Oct 2;5(1):48.
27. Turco MC, Lamberti A, Bisogni R, Romano MF, Petrella A, Ammirante M, Rosati A, Davenia M, Arra C, **Spugnini E**, Bonelli P, Venuta S. Modulation of cell apoptosis by AIR. Leukemia 2007; 21: 2557-2559.
28. **Spugnini EP**, Arancia G, Porrello A, Colone M, Formisano G, Stringaro A, Citro G, Molinari A. Ultrastructural modifications induced by “electroporation” on melanoma xenografts. Micr Res Tech.2007; 70: 1041-1050.
29. **Spugnini EP**, Citro G, Dotsinsky I, Mudrov N, Mellone P, Baldi A. Ganglioneuroblastoma in a cat: a rare neoplasm treated with electrochemotherapy. Vet J 2008; 178: 291-293.
30. **Spugnini EP**, Vincenzi B, Citro G, Tonini G, Dotsinsky I, Mudrov N, Baldi A. Electrochemotherapy for the treatment of squamous cell carcinoma in cats: a preliminary report. Vet J 2009; 179: 117-120.
31. **Spugnini EP**, Pagotto A, Zazzera F, D’ Avino A, Caruso G, Baldi A. Cutaneous T cell lymphoma in an African hedgehog (*Atelerix Albiventris*). In Vivo. 2008; 22: 43-46.
32. **Spugnini EP**, Citro G, Baldi A. Potential role of electrochemotherapy for the treatment of soft tissue sarcoma: first insights from preclinical studies in animals. Int J Biochem. Cell Biol. 2008; 40: 159-163.
33. **Spugnini EP**, Vincenzi B, Betti G, Cordahi F, Dotsinsky I, Mudrov N, Citro G, Baldi A. Surgery and electrochemotherapy for high grade soft tissue sarcoma in a dog. Vet Rec 2008; 162: 186-188.

34. **Spugnini EP**, Dotsinsky I, Mudrov N, Cardosi G, Citro G, Baldi A. Biphasic pulses enhance bleomycin efficacy in a spontaneous canine perianal tumors model. *J Exp Clin Cancer Res* 2007; 26: 483-487.
35. **Spugnini EP**, Campioni M, D'Avino A, Caruso G, Citro G, Baldi A. Cell-cycle molecules in mesothelioma: an overview. *J Exp Clin Cancer Res* 2007; 26: 443-449.
36. **Spugnini EP**, Dotsinsky I, Mudrov N, Bufalini M, Giannini G, Citro G, Feroce F, Baldi A. Adjuvant electrochemotherapy for incompletely excised anal sac carcinoma in a dog. *In Vivo* 2008; 22: 47-50
37. **Spugnini EP**, Dotsinsky I, Mudrov N, De Luca A, Codini C, Citro G, D' Avino A, Baldi A. Successful rescue of a apocrine gland carcinoma metastatic to the cervical lymph nodes by mitoxantrone coupled with trains of permeabilizing electric pulses (electrochemotherapy). *In Vivo* 2008; 22: 51-54
38. **Spugnini EP**, Crispi S, Scarabelli A, Caruso G, Citro G, Baldi A. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations. *J Exp Clin Cancer Res* 2008; 27: 6.
39. **Spugnini EP**, Vincenzi B, Caruso G, Baldi A, Citro G, Santini D, Tonini G. Zoledronic acid for the treatment of appendicular osteosarcoma in a dog. *J Sm An Pract.* 2009; 59: 44-46.
40. Baldi A, Mottotese M, Vincenzi B, Campioni M, Mellone P, Di Martino M, Di Crescenzo VC, Visca P, Menegozzo S, **Spugnini EP**, Citro G, Ceribelli A, Mirri A, Chien J, Schridhar V, Ehrmann M, Santini M, Facciolo F. The serine protease HTRA 1 is a novel prognostic factor for human mesothelioma. *Pharmacogenomics* 2008; 9: 1069-1077.
41. **Spugnini EP**, Dotsinsky I, Mudrov N, Citro G, D' Avino A, Baldi A. Biphasic pulses enhance bleomycin efficacy in a spontaneous canine genital tumor model of chemoresistance: Sticker sarcoma. *J Exp Clin Cancer Res* 2008; 27: 58.
42. Campioni M, Ambrogi V, Pompeo E, Citro G, Castelli M, **Spugnini EP**, Gatti A, Cardelli P, Lorenzon L, Baldi A, Mineo TC. Identification of genes down-regulated during lung cancer progression: a cDNA array study. *J Exp Clin Cancer Res.* 2008 Sep 15;27:38.
43. Assin R, Baldi A, Citro G, **Spugnini EP**. Prostate as sole unusual recurrence site of lymphoma in a dog. *In Vivo.* 2008; 22: 755-757.
44. **Spugnini EP**, Dotsinsky I, Mudrov N, Citro G, Cardelli P, Caruso G, Baldi A. Electrochemotherapy-Induced radiation recall in a cat. *In Vivo.* 2008; 22: 751-753.
45. **Spugnini EP**, Gargiulo M, Assin R, D' Avino A, Mellone P, Cardelli P, Citro G, Baldi A. Adjuvant

carboplatin for the treatment of intestinal carcinoid in a dog. *In Vivo*. 2008; 22: 759-761.

46. **Spugnini EP**, Citro G, Baldi A. Adjuvant electrochemotherapy in veterinary patients: a model for the planning of future therapies in humans. *J Exp Clinical Cancer Res* 2009; 28: 114.
47. Crispi S, Cardillo I, **Spugnini EP**, Citro G, Menegozzo S, Baldi A. Biological Agents Involved in Malignant Mesothelioma: Relevance as Biomarkers or Therapeutic Targets. *Curr Cancer Drug Targets*. 2010; 10(1):19-26
48. **Spugnini EP**, Filipponi M, Romani L, Dotsinsky I, Mudrov N, Citro G, Baldi A. Bilateral pleomorphic rhabdomyosarcoma in a cat treated with electrochemotherapy. *J Small An Pract* 2010; 51(6):330-2
49. Signorile PG, **Spugnini EP**, Mita L, Mellone P, D'Avino A, Bianco M, Diano N, Caputo L, Rea F, Viceconte R, Portaccio M, Viggiano E, Citro G, Pierantoni R, Sica V, Vincenzi B, Mita DG, Baldi F, Baldi A. Prenatal exposure of mice to bisphenol a elicits an endometriosis-like phenotype in female offspring. *Gen Comp Endocrinol* 2010 168(3):318-325.
50. **Spugnini EP**, Mezzanotte F, Freri L, Betti G, Citro G, Baldi A. Cyproterone acetate-induced mammary carcinoma in two male cats. *J Feline Med Surg* 2010;12: 515-516.
51. **Spugnini EP**, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. *J Exp Clin Cancer Res*. 2010 May 8;29:44.
52. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, **Spugnini EP**, Baldi A, Faiola F, Adamo S, Coletti D. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. *BMC Cancer*. 2010; 10:363.
53. Baldi A, De Luca A, Esposito V, Campioni M, **Spugnini EP**, Citro G. Tumor suppressors and cell-cycle proteins in lung cancer. *Pathology Research International*. 2011; 2011: 605042.
54. **Spugnini EP**, Vincenzi B, Citro G, Baldi A. Evaluation of cisplatin (CDDP) as a electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in dogs. *Journal of Veterinary Internal Medicine*, 2011; 25: 407-411.

55. **Spugnini EP**, Biroccio A, De Mori R, Scarsella M, D' Angelo C, Baldi A, Leonetti C. Electroporation increases antitumoral efficacy of the bcl-2 antisense g3139 and chemotherapy in a human melanoma xenograft. *Journal of Translational Medicine*. 2011;9:152.
56. **Spugnini EP**, D' Alterio GL, Dotsinsky I, Mudrov T, Dragonetti E, Murace G, Citro G, Baldi A. Electrochemotherapy for the treatment of multiple melanomas in a horse. *Journal of Equine Veterinary Science*. 2011; 31: 430-433.
57. Mara Campioni, Anna Severino, Lucrezia Manente, Antonio De Luca, Raffaele La Porta, Antonio Vitiello, Paola Fiore, Stefano Toldo, **Enrico P. Spugnini**, Marco G. Paggi, Alfonso Baldi. Identification of protein-protein interactions of human HtrA1. *Frontiers in Bioscience*. 2011; 3:1493-1499.
58. Alfonso Baldi, Maria Rosaria Boccellino, Aldo Donizetti, Maria Teresa Piccolo, Raffaele La Porta, Lucio Quagliuolo, **Enrico P. Spugnini**, Irene Cardillo, Francesca Cordero, Gennaro Citro, Massimo Menegozzo, Raffaele A. Calogero, Stefania Crispi. Apoptosis induced by Piroxicam plus Cisplatin combined treatment is triggered by p21 overexpression in mesothelioma. *PlosOne*, 2011;6(8):e23569.
59. Mita L, Baldi A, Diano N, Viggiano E, Portaccio M, Nicolucci C, Grumiro L, Menale C, Mita DG, **Spugnini EP**, Viceconte R, Citro G, Pierantoni R, Sica V, Marino M, Signorile PG, Bianco M. Differential accumulation of BPA in some tissues of offspring of Balb-C mice exposed to different BPA doses. *Environ Toxicol Pharmacol*. 2011; 33(1):9-15.
60. **Spugnini EP**, Renaud SM, Buglioni S, Carocci F, Dragonetti E, Murace R, Cardelli P, Vincenzi B, Baldi A, Citro G. Electrochemotherapy with cisplatin enhances local control after surgical ablation of fibrosarcoma in cats: an approach to improve the therapeutic index of highly toxic chemotherapy drugs. *J Transl Med*. 2011; 9:152.
61. **Enrico P Spugnini**, Alfonso Baldi, Sabrina Buglioni, Francesca Carocci, Giulia Milesi de Bazzichini, Gianluca Betti, Ilaria Pantaleo, Francesco Menicagli, Gennaro Citro and Stefano Fais. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. *J. Transl Med*. 2011; 9:221.
62. Pietro G. Signorile, **Enrico P. Spugnini**, Gennaro Citro, Rosa Viceconte, Bruno Vincenzi, Feliciano

Baldi, Alfonso Baldi. Endocrine disruptors in utero cause ovarian damages linked to endometriosis Baldi, Frontiers in Bioscience. 2012; 4:1724-30.

63. Stefania Meschini, Maria Condello, Pasquale Lista, Bruno Vincenzi, Alfonso Baldi, Gennaro Citro, Giuseppe Arancia, **Enrico P. Spugnini**. Electroporation adopting trains of biphasic pulses enhances in vitro and in vivo the cytotoxic effect of doxorubicin on multidrug resistant colon adenocarcinoma cells (LoVo) European Journal Of Cancer Accettato per pubblicazione.
64. Vincenzo Esposito, Alessandra Verdina, **Enrico P. Spugnini**, Rosaria Viglietti, Roberto Parrella, Pasquale Pagliano, Giovanni Parrella, Rossella Galati, Antonio De Luca, Alfonso Baldi, Vincenzo Montesarchio, Antonio Chirianni. Amprenavir PI3K/AKT independent anti-tumoral properties in an in vitro and in vivo model of epatocarcinoma. J Cell Physiol 2013 Mar;228(3):640-5.
65. **Spugnini EP**, Fanciulli M, Citro G, Cardelli P, Baldi A. Electrochemotherapy in veterinary patients: a model for the implementation of loco-regional therapies in humans. Future Oncology. 2012 Jul;8(7):829-37.
66. Folgiero V, Di Carlo SE, Bon G, **Spugnini EP**, Di Benedetto A, Germoni S, Pia Gentileschi M, Accardo A, Milella M, Morelli G, Bossi G, Mottolese M, Falcioni R. Inhibition of p85, the non-catalytic subunit of phosphatidylinositol 3-kinase, exerts potent antitumor activity in human breast cancer cells. Cell Death Dis. 2012 Dec 6;3:e440.
67. **Spugnini EP**, Cardillo I, Fanciulli M, Crispi S, Vincenzi B, Boccellino M, Quagliuolo L, Baldi A. Electroporation as a strategy to promote HtrA1 gene uptake and chemotherapy efficacy in a mouse model of mesothelioma. Frontiers in Bioscience 2013; 5:974-81
68. Scacco L, Bolaffio C, Romano A, Fanciulli M, Baldi A, **Spugnini EP**. Adjuvant electrochemotherapy increases local control in a recurring equine anal melanoma. Journal of Equine Veterinary Science. 2013; 33: 637-639.
69. Cardillo I, **Spugnini EP**, Galluzzo P, Contestabile M, Dell'anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer. Future Oncol. 2013; 9:1375-88.
70. **Spugnini EP**, Di Tosto G, Salemme S, Pecchia L, Fanciulli M, Baldi A. Electrochemotherapy for the treatment of recurring aponeurotic fibromatosis in a dog. Canadian Veterinary Journal 2013; 54: 606-608.
71. **Spugnini EP**, Melillo A, Quagliuolo L, Boccellino M, Vincenzi B, Pasquali P, Baldi A. Definition of Novel Electrochemotherapy Parameters and Validation of their In Vitro and In Vivo Effectiveness. J Cell Physiol. 2014 Jan 9.
72. **Spugnini EP**, Baldi A. Electrochemotherapy in veterinary oncology: from rescue to first line therapy. Methods Mol Biol. 2014;1121:247-56.

73. **Spugnini EP**, Buglioni S, Carocci F, Francesco M, Vincenzi B, Fanciulli M, Fais S. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. *J Transl Med.* 2014; 12:225.
74. **Spugnini EP**, Sonveaux P, Stock C, Perez-Sayans M, De Milito A, Avnet S, Garcia AG, Harguindey S, Fais S. Proton channels and exchangers in cancer. *Biochim Biophys Acta.* 2014 Oct 20 [Epub ahead of print].
75. Lanza A, Baldi A, **Spugnini EP**. Surgery and electrochemotherapy for the treatment of cutaneous squamous cell carcinoma in a yellow-bellied slider (*Trachemys scripta scripta*). *J Am Vet Med Assoc.* 2015 Feb 15;246(4):455-7.
76. Lugini L, Federici C, Borghi M, Azzarito T, Marino ML, Cesolini A, **Spugnini EP**, Fais S. Proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. *J Enzyme Inhib Med Chem.* 2015 May 28:1-8.[Epub ahead of print]
77. **Spugnini EP**, Pizzuto M, Filipponi M, Romani L, Vincenzi B, Menicagli F, Lanza A, De Girolamo R, Lomonaco R, Fanciulli M, Spriano G, Baldi A. Electroporation Enhances Bleomycin Efficacy in Cats with Periocular Carcinoma and Advanced Squamous Cell Carcinoma of the Head. *J Vet Intern Med.* 2015; 29(5):1368-75.
78. Walsh M, Fais S, **Spugnini EP**, Harguindey S, Abu Izneid T, Scacco L, Williams P, Allegrucci C, Rauch C, Omran Z. Proton pump inhibitors for the treatment of cancer in companion animals. *J Exp Clin Cancer Res.* 2015; 34:93.
79. Taylor S, **Spugnini EP**, Assaraf YG, Azzarito T, Rauch C, Fais S. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. *Drug Resist Updat.* 2015; 23:69-78.
80. **Spugnini EP**, Azzarito T, Fais S, Fanciulli M, Baldi A. Electrochemotherapy as first line cancer treatment: experiences from veterinary medicine in developing novel protocols *Current Cancer Drug Targets.* 2015;16(1):43-52.
81. Canitano A, Iessi E, **Spugnini EP**, Federici C, Fais S. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. *Cancer Lett.* 2016;376(2):278-83.
82. Menicagli F, Lanza A, Sbrocca F, Baldi A, **Spugnini EP**. A case of advanced second-degree atrioventricular block in a ferret secondary to lymphoma. *Open Vet J.* 2016;6(1):68-70.

83. Gentileschi MP, Lattanzio C, Menicagli F, Vincenzi B, Cigliana G, Baldi A, Blandino G, Muti P, Fanciulli M, **Spugnini EP**. Dietary Protective Effects Against Hepatocellular Carcinoma Development in Mdr2-/- Knockout Mice. *In Vivo*. 2016;30(4):445-50.
84. Azzarito T, Lugini L, **Spugnini EP**, Canese R, Gugliotta A, Fidanza S, Fais S. Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice. *PLoS One*. 2016;11(7):e0159763.
85. Spugnini EP, Fais S, Azzarito T, Baldi A. Novel Instruments for the Implementation of Electrochemotherapy Protocols: From Bench Side to Veterinary Clinic. *J Cell Physiol*. 2017 Mar;232(3):490-495.
86. Lugini L, Sciamanna I, Federici C, Iessi E, Spugnini EP, Fais S. Antitumor effect of combination of the inhibitors of two new oncotargets: proton pumps and reverse transcriptase. *Oncotarget*. 2017 Jan 17;8(3):4147-4155.
87. Spugnini EP, Bolaffio C, Scacco L, Baldi A. Electrochemotherapy increases local control after incomplete excision of a recurring penile fibrosarcoma in a stallion. *Open Vet J*. 2016;6(3):234-237.
88. Spugnini E, Fais S. Proton pump inhibition and cancer therapeutics: A specific tumor targeting or it is a phenomenon secondary to a systemic buffering? *Semin Cancer Biol*. 2017 Jan 11. pii: S1044-579X(17)30003-2.
89. Lanza A, Pettorali M, Baldi A, Spugnini EP. Surgery and electrochemotherapy treatment of incompletely excised mammary carcinoma in two male pet rats (*Rattus norvegicus*). *J Vet Med Sci*. 2017 Mar 23;79(3):623-625.
90. Iessi E, Logozzi M, Lugini L, Azzarito T, Federici C, Spugnini EP, Mizzoni D, Di Raimo R, Angelini DF, Battistini L, Cecchetti S, Fais S. Acridine Orange/exosomes increase the delivery and the effectiveness of Acridine Orange in human melanoma cells: A new prototype for theranostics of tumors. *J Enzyme Inhib Med Chem*. 2017 Dec;32(1):648-657.
91. Spugnini EP, Menicagli F, Pettorali M, Baldi A. Ultrasound guided electrochemotherapy for the treatment of a clear cell thymoma in a cat. *Open Vet J*. 2017;7(1):57-60.
92. Spugnini EP, Bolaffio C, Scacco L, Baldi A. Isolated limb perfusion electrochemotherapy for the treatment of an advanced squamous cell carcinoma of the hoof in a mare. *Open Vet J*. 2017;7(2):192-196.
93. Pasquali P, Freitas-Martinez A, Gonzalez S, Spugnini EP, Baldi A. Successful treatment of plantar warts with intralesional bleomycin and electroporation: pilot prospective study. *Dermatol Pract Concept*. 2017 Jul 31;7(3):21-26.
94. Pasquali P, Spugnini EP, Baldi A. Successful Treatment of a Keratoacanthoma with Electrochemotherapy: A Case Report. *Dermatol Ther (Heidelb)*. 2018 Mar;8(1):143-146.
95. Carafà V, Nebbioso A, Cuomo F, Rotili D, Cobellis G, Bontempo P, Baldi A, Spugnini EP, Citro G, Chambery A, Russo R, Ruvo M, Ciana P, Maravigna L, Shaik J, Radaelli E, De Antonellis P, Tarantino D, Pirolli A, Ragno R, Zollo M, Stunnenberg HG, Mai A, Altucci L. RIP1-HAT1-SIRT Complex

Identification and Targeting in Treatment and Prevention of Cancer. Clin Cancer Res. 2018 Jun 15;24(12):2886-2900.

96. Baldi A, Lanza A, Menicagli F, Signorile PG, Spugnini EP. Histological and Immunohistochemical Characterization of a Case of Endometriosis in a Guinea Pig (*Cavia tschudii*). Case Rep Vet Med. 2017 May 8; 2017:4594510.
97. Spugnini EP, Lanza A, Sebasti S, Baldi A. Electrochemotherapy palliation of an oral squamous cell carcinoma in an African hedgehog (*Atelerix albiventris*). Vet Res Forum. 2018;9(4):379-381.
98. Spugnini EP, Logozzi M, Di Raimo R, Mizzoni D, Fais S. A Role of Tumor-Released Exosomes in Paracrine Dissemination and Metastasis. Int J Mol Sci. 2018;19(12):3968
99. Lanza A, Baldi A, Rossi G, Spugnini EP. Electrochemotherapy for the treatment of an incompletely excised subcutaneous low-grade epithelioid hemangioendothelioma in a budgerigar parakeet (*Melopsittacus undulatus*). Open Vet J. 2019 Oct;9(3):269-272.
100. Condello M, Pellegrini E, Spugnini EP, Baldi A, Amadio B, Vincenzi B, Occhionero G, Delfino S, Mastrodonato F, Meschini S. Anticancer activity of "Trigno M", extract of *Prunus spinosa* drupes, against in vitro 3D and in vivo colon cancer models. Biomed Pharmacother. 2019;118:109281.
101. Spugnini EP, Baldi A. Electrochemotherapy in Veterinary Oncology: State-of-the-Art and Perspectives. Vet Clin North Am Small Anim Pract. 2019;49(5):967-979.
102. Pillai SR, Damaghi M, Marunaka Y, Spugnini EP, Fais S, Gillies RJ. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. 2019;38(1-2):205-222.
103. Logozzi M, Spugnini E, Mizzoni D, Di Raimo R, Fais S. Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer Metastasis Rev. 2019; 38(1-2):93-101.
104. Spugnini EP, Vincenzi B, Amadio B, Baldi A. Adjuvant electrochemotherapy with bleomycin and cisplatin combination for canine soft tissue sarcomas: A study of 30 cases. Open Vet J. 2019;9(1):88-93.
105. Spugnini EP, Fais S. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opin Ther Pat. 2020 Jan;30(1):15-25.
106. Spugnini EP, Scimeca M, Amadio B, Cortese G, Fanciulli M, Vincenzi B, De Luca A, Baldi A. Definition of a Novel Plasmid-Based Gene Transfection Protocol of Mammalian Skeletal Muscles by Means of In Vivo Electroporation. Int J Mol Sci. 2020; 21(18):6494.
107. Dos Anjos DS, Sierra OR, Spugnini EP, De Nardi AB, Fonseca-Alves CE. Comparison of two different doses of bleomycin in electrochemotherapy protocols for feline cutaneous squamous cell carcinoma nonsegregated from ultraviolet light exposure. Sci Rep. 2020; 10(1):18362.
108. Dos Anjos DS, Buosi RG, Roratto I, Mesquita LDR, Matiz ORS, Fonseca-Alves CE, Spugnini EP. Preliminary assessment of electrochemotherapy feasibility in dogs with vesical transitional cell carcinoma. Vet Res Forum. 2020; 11(3):289-293.

109. Bruno T, De Nicola F, Corleone G, Catena V, Goeman F, Pallocca M, Sorino C, Bossi G, Amadio B, Cigliana G, Ricciardi MR, Petrucci MT, Spugnini EP, Baldi A, Cioce M, Cortese G, Mattei E, Merola R, Gianelli U, Baldini L, Pisani F, Gumenyuk S, Mengarelli A, Höpker K, Benzing T, Vincenzi B, Floridi A, Passananti C, Blandino G, Iezzi S, Fanciulli M. Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma. *Blood Adv.* 2020; 4(22):5616-5630.
110. Spugnini EP, Vincenzi B, Carocci F, Bonichi C, Menicagli F, Baldi A. Combination of bleomycin and cisplatin as adjuvant electrochemotherapy protocol for the treatment of incompletely excised feline injection-site sarcomas: A retrospective study. *Open Vet J.* 2020;10(3): 267-271.
111. Spugnini EP, Menicagli F, Giaconella R, Zanni F, Camponi C, De Luca A, Santoro A, Baldi A. Filling the gap between histology and cytology: description of an innovative technology (Cytomatrix) to increase the diagnostic effectiveness of fine needle aspirates data. *J Clin Pathol.* 2021; 74:269-270
112. Valenti P, Menicagli F, Baldi A, Barella G, Catalucci C, Attorri V, Spugnini EP. Evaluation of electrochemotherapy in the management of apocrine gland anal sac adenocarcinomas in dogs: A retrospective study. *Open Vet J.* 2021; 11(1):100-106.
113. Condello M, D'Avack G, Vona R, Spugnini EP, Scacco L, Meschini S. Electrochemotherapy with Mitomycin C Potentiates Apoptosis Death by Inhibiting Autophagy in Squamous Carcinoma Cells. *Cancers* 2021, 13, 3867.
114. Spugnini EP, Scacco L, Bolaffio C, Baldi A. Electrochemotherapy for the treatment of cutaneous solid tumors in Equids: A retrospective study. *Open Vet J* 2021, 11(3): 385-389
115. Condello M, D'Avack G, Spugnini EP, Meschini S. Electrochemotherapy: An Alternative Strategy for Improving Therapy in Drug-Resistant SOLID Tumors. *Cancers (Basel).* 2022; 14:4341.

116. Capitoli di libri

Spugnini EP, Baldi A, Citro G. Pulse mediated chemotherapy (electrochemotherapy) studies in animals and their translation to humans. *Recent Res. Devel. Pharmacol.* pp 1-28, 2006, Research Signpost, Kerala India.

Spugnini EP, Seiler G, Keene B. Canine mesothelioma: an epidemiological and preclinical model. In: Baldi A (Editor) "Mesothelioma from benchside to the clinic" Nova Science NY. 2008, pp 537-546

Spugnini EP et al. Chapters 7,13,14, 15. In: *Electroporation in Laboratory and Clinical Investigations*. Edited by Nova Science, New York.

Spugnini EP. Electrochemotherapy in dermatological Oncology. In: *Skin Cancer: A Practical Approach*. Edited by: Humana Press (Springer) New York USA pag 435-444.

Spugnini EP, Baldi A. Electrochemotherapy in veterinary oncology: from rescue to first line therapy. In: *Electroporation Protocols Preclinical and Clinical Gene Medicine Series: Methods in Molecular Biology*, Vol. 1121 pag 247-56. Li, S., Cutrera, J., Heller, R., Teissie, J. (Eds.) 2nd ed. 2014, Humana Press

Spugnini EP. Electrochemotherapy in feline oncology. In: Little S. (Editor). *August consultations in feline internal medicine* pag 572-577. Saunders Edition, Saint Louis, MO, USA.

Spugnini EP, Fais S. Vacuolar-ATPase proton pump inhibition in cancer therapy: veterinary and human experience. In: Koltai T, Reshkin SJ, Hardinguey S. (Editors) *An innovative approach to understanding and treating cancer: targeting pH. From etiopathogenesis to new therapeutic avenues*. Pp 509-522. 2020, Academic Press (Elsevier)

LETTURE MAGISTRALI &
COMUNICAZIONI A
CONGRESSI

July 1999	Companion Animals with advanced neoplasms as a model for their human counterparts.	<i>National Cancer Institute Sofia, Bulgaria</i>
September 2002	Electrochemotherapy of Companion Animals with advanced neoplasms.	<i>Veterinary Teaching Hospital, University of Illinois, Urbana U.S.A.</i>
September 2002	Combined surgery and electrochemotherapy for the treatment of feline sarcomas.	<i>22nd Veterinary Cancer Society Annual Conference, 2002 New York, NY, U.S.A.</i>
December 2002	Spontaneous cancer models: the role of companion animals	<i>Regina Elena Cancer Institute Rome, Italy</i>
January 2003	Spontaneous cancer models: the role of companion animals	<i>University of Salerno Faculty of Pharmacology Salerno, Italy</i>
April 2003	Tumors in domestic animals as a model for humans: contribution to the development of novel electrochemotherapy protocols	<i>Pascale Cancer Institute Naples, Italy</i>
May 2003	Myeloproliferative Syndromes in dogs and cats	<i>Course of hematology for Veterinarian Medical History Academy Rome, Italy</i>
May 2004	Development of chemotherapy protocols in companion animals: preclinical and epidemiological implications.	<i>Workshop Veterinary Epidemiology: state of the art and novel trends. National Institute of Health, Rome, Italy</i>
December 2004	Animal models of apoptosis-mediated antitumor therapy (electrochemotherapy) and their translation to humans	<i>Yearly symposium ONLUS-AICC (Italian branch of the European Tissue Culture Society) Naples, Italy</i>

December 2004	Feline and canine lymphoma and leukemias: what's new	<i>Continuing Education Course for Veterinarians Rome, Italy</i>
February 2005	Transition from laboratory to clinical application of a novel apoptosis-mediated cancer destruction technique.	<i>The Ilar Preclinical/clinical interface conference. Amsterdam, The Netherland</i>
April 2005	Spontaneous neoplasms of pets: a preclinical model to develop and test novel therapeutic strategies	<i>Oncology Seminars University Campus Biomedico Rome, Italy</i>
September 2005	Analysis of COX-2 involvement in the pathogenesis and therapy of human mesothelioma A. Baldi, E.P. Spugnini, et al.	<i>National Congress SIAPEC-IAP Chieti, Italy</i>
October 2005	Use of the HIV protease inhibitor indinavir to block hepatocarcinoma growth in nude mice. <i>V. Esposito, A. Baldi, E. Spugnini, V. Montesarchio, A.M. Groeger, A. De Luca, E. Palessandolo, G. Cortese, A. Chirianni (Naples, Italy) (15').</i>	<i>The International Institute of Anticancer Research, yearly conference, Rome, Italy</i>
December 2005	Delivery of anticancer drugs through biphasic pulses as a rescue for advanced tumors: first results in companion animals	<i>Workshop Mechanisms of chemoresistance and radioresistance in tumor cells. National Institute of Health, Rom, Italy</i>
October 2006	Feline and canine sarcomas: diagnosis, prognosis and treatment	<i>Veterinary Association of Viterbo, Italy</i>
May 2007	Electrochemotherapy of solid tumors: an update on a novel anticancer therapy	<i>Swiss Association of Small Animals Veterinarians</i>
June 2007	Pulse-Mediated chemotherapy of solid tumors (electrochemotherapy): recent developments of a novel anticancer therapy	<i>25th Annual ACVIM Meeting Seattle, USA</i>

June 2007	Oncology in companion animals: what's new?	<i>Yearly AVULP (Association Veterinary Practitioners of Umbria) meeting</i>
January 2008	Pre-Clinical Models in Oncology	<i>Presentation to the Scientific Advisory Board of the Regina Elena Cancer Institute</i>
February 2008	Pulse-Mediated chemotherapy of solid tumors (electrochemotherapy): recent developments of a novel anticancer therapy	<i>University of Glasgow (UK), Small Animal Hospital</i>
March 2008	Adjuvant CDDP-based electrochemotherapy for the treatment of incompletely excised mast cell tumors in dogs	<i>1st Worldvet cancer Meeting February 28th-March 1st Copenhagen (DK)</i>
May 2008	Electrochemotherapy: indirect evidence of involvement of the immune system. Preliminary findings from animal studies.	International Symposium "Immunotherapy of cancer – clinical results and future goals" May 8 and 9, 2008, Sofia, Bulgaria
October 2008	Electrochemotherapy for the treatment of mast cell tumors in dogs	Meeting Sioncovet October 12, 13, 2008, Cremona, Italy
October 2008	Pulse-Mediated chemotherapy of solid tumors in pets (electrochemotherapy): recent developments of a novel anticancer therapy	8 th IAR International Conference of Anticancer Research
March 2009	Research in animal models for endometriosis	High Tech in endometriosis and infertility March 4, 2009, Rome Italy

March 2009	Molecular mechanisms of pathogenesis and progression in malignant mesothelioma: possible therapeutic applications from animal studies	<i>University of Glasgow (UK), Small Animal Hospital</i>
June 2009	Evaluation of Cisplatin (CDDP) as a electrochemotherapy agent for the treatment of incompletely excised mast cell tumors in Dogs	<i>27th Annual ACVIM Meeting, 3-6 June 2009, Montreal, Canada</i>
September 2009	Adnexial tumors of companion animals as a model for humans: results in the field of electrochemotherapy	<i>Preclinical Oncology Models: scientific, technical and ethical Aspects. September 20-21 2009, Genova, Italy</i>
April 2010	Preclinical models in biomedicine, biomechanical prosthesis, ultrasonography, and electrochemotherapy in animals.	<i>Centre of Biomedical Engineering "Ivan Daskalov" Sofia Bulgaria</i>
April 2010	Pulse-mediated chemotherapy of solid tumors in pets (electrochemotherapy): recent developments of a novel anticancer therapy	<i>Bulgarian Academy of Sciences Sofia Bulgaria</i>
June 2010	Pulse-Mediated Chemotherapy Of Solid Tumors (Electrochemotherapy): Recent Developments Of A Novel Anticancer Therapy	<i>28th ACVIM 2010 Forum Anaheim USA</i>
September 2010	Proton pump inhibitors as anti vacuolar-ATPases drugs: preliminary findings in companion animals with spontaneous neoplasms	<i>ISPDC Meeting September 27, 28 Rome Italy</i>
November 2010	Paraneoplastic syndromes and oncology emergencies	<i>AMVAC Meeting November 12, 13 Sinaia Romania</i>

November 2010	Update on mast cell tumors in dogs and cats	<i>AMVAC Meeting November 12, 13 Sinaia Romania</i>
November 2010	Electrochemotherapy and electrogenetherapy: new approaches in anti-cancer therapy in cats and dogs	<i>Faculty of Veterinary Medicine University of Gent Gent Belgium</i>
December 2010	Chemotherapy and tumor vaccine in veterinary oncology	<i>Workshop "Human and veterinary oncology: comparative aspects and future applications" December 3, 2010 Faculty of Medicine University of Tor Vergata Rome Italy</i>
May 2011	Novel strategies to modulate cancer microenvironment (tumor acidity) increasing chemo-response: electroporation and proton pump inhibitors	<i>Faculty of Veterinary Medicine University of Nottingham Nottingham UK</i>
June 2011	Anti vacuolar-ATPases drugs: a novel anticancer strategy	<i>29th Annual ACVIM Meeting, 15-18 June 2011, Denver, USA</i>
June 2011	Electrochemotherapy: protocol considerations & research summary	<i>29th Annual ACVIM Meeting, 3-6 June 2011, Denver, USA</i>
November 2011	Electroporation enhances bleomycin efficacy in a spontaneous feline head and neck carcinoma model	<i>XXVII European Federation Congress of the International College of Surgeons, 11-12 November 2011, Rome, Italy</i>
March 2012	Electroporation enhances bleomycin efficacy in cats with advanced head and neck carcinoma	<i>2nd World Veterinary Cancer Congress March 1-3 2012, Paris, France</i>

April 2013	"Proton pump inhibitors and alkalizing agents as rescue in chemoresistant tumors and as chemosensitizers in metronomic chemotherapy: a veterinary Phase I/II trial"	<i>Italy-Japan joint symposium on tumor acidity. April 27 2013, Kyoto, Japan</i>
May 2013	Radiation therapy: principles, indications and complications, Part I	<i>Practical clinical oncology of the dog and the cat. May 3-5, 2013 Perugia Italy</i>
May 2013	Radiation therapy: principles, indications and complications, Part II	<i>Practical clinical oncology of the dog and the cat. May 3-5, 2013 Perugia Italy</i>
May 2013	Alternative therapies: electrochemotherapy and beyond	<i>Practical clinical oncology of the dog and the cat. May 3-5, 2013 Perugia Italy</i>
June 2013	Lymphoma in pet rabbits	<i>Oncology, the new frontier of the exotic animals medicine. SCIVAC National Meeting, 2 June 2013, Rimini, Italy</i>
June 2013	Electrochemotherapy in exotic pets	<i>Oncology, the new frontier of the exotic animals medicine. SCIVAC National Meeting, 2 June 2013, Rimini, Italy</i>
June 2013	Targeting Cancer Acid Environment: A Novel Anticancer Strategy	<i>31st Annual ACVIM Meeting, 12-15 June 2013, Seattle, USA</i>
June 2013	Electroporation in Veterinary Medicine: Riding the Electrical Waveform	<i>31st Annual ACVIM Meeting, 12-15 June 2013, Seattle, USA</i>

September 2013	Soft tissue sarcomas: part I	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Soft tissue sarcomas: part II	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Management of canine lymphoma: part I	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Management of canine lymphoma: part II	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Plasma cell tumors and Multiple Myeloma: a comparison between dogs and cats	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Management of histiocytic tumors	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
September 2013	Overview of oncology in exotics	<i>Practical clinical oncology of the dog and the cat. September 20-22, 2013 Perugia Italy</i>
October 2013	Proton pump inhibitors as anti vacuolar-ATPases drugs: preliminary findings in companion animals with spontaneous neoplasms treated with metronomic chemotherapy	<i>4th Annual meeting of the International Society for Proton Dynamics in Cancer, October 10-12, 2013, Munich, Germany</i>

December 2013	Electroporation in Oncology	<i>University of Missouri, invited lecture December 8h</i>
June 2014	Melanoma: the role of electrochemotherapy	<i>SCIVAC National Meeting, 2 June 2014, Rimini, Italy</i>
June 2015	Electroporation in Oncology: Current Concepts	<i>33rd Annual ACVIM Meeting, 3-6 June 2015, Indiana, USA</i>
June 2015	Cancer Acid Environment: Implications for Theranostic Approaches	<i>33rd Annual ACVIM Meeting, 3-6 June 2015, Indiana, USA</i>
October 2015	Electrochemotherapy for skin tumors: translational medicine approaches	<i>Futura Onlus Foundation Meeting, October 24, Rome, Italy</i>
June 2016	Electroporation in Oncology: Clinical Applications and Future Perspectives in Equine Medicine	<i>34th Annual ACVIM Meeting, June 8- 11, 2016, Denver Colorado, USA</i>
June 2016	Electroporation in Oncology: Clinical Applications and Future Perspectives	<i>34th Annual ACVIM Meeting, June 8- 11, 2016, Denver Colorado, USA</i>
October 2016	Neoplasia and tumor microenvironment: state of the art and preliminary experiences in equine oncology	<i>22nd International Congress SIVE (Italian Society Equine Veterinarians), October 13-15 Milan, Italy</i>

November 2016	Electroporation in veterinary medicine: general concepts	<i>I workshop on Electrochemotherapy I Symposium on Small Animal Oncology November 11-13th, 2016 - Ribeirão Preto, Brazil</i>
November 2016	Electrochemotherapy in veterinary medicine: state of the art and clinical cases	<i>I workshop on Electrochemotherapy I Symposium on Small Animal Oncology November 11-13th, 2016 - Ribeirão Preto, Brazil</i>
November 2016	Cancer Acid Environment: Implications for Theranostic Approaches	<i>I workshop on Electrochemotherapy I Symposium on Small Animal Oncology November 11-13th, 2016 - Ribeirão Preto, Brazil</i>
April 2017	Electroporation in head and neck cancer: clinical applications and future perspectives	<i>Esvonc Congress April 20-22 Lyon, France</i>
October 2017	Electrochemotherapy in skin tumors: translational studies on animal models	<i>Futura Onlus Congress, October 14, 2017</i>
June 2018	Adjuvant electrochemotherapy with bleomycin and cisplatin combination for the canine soft tissue sarcoma: 30 cases	<i>ACVIM Forum June 14-16, 2018</i>
June 2018	Understanding and countering tumor acidity: clinical results and future perspectives	<i>ACVIM Forum June 14-16, 2018</i>

February 2019	Principles of electrochemotherapy: how, where and when	<i>XV National Unisvet Congress</i>
June 2019	Tumor microenvironment: the novel frontier of oncology	<i>ANZCVS Science Week Congress, July 4-6, Gold Coast, Australia</i>
June 2019	Electrochemotherapy in small animals	<i>ANZCVS Science Week Congress, July 4-6, Gold Coast, Australia</i>
June 2019	Electroporation in veterinary medicine: general concepts	<i>ANZCVS Science Week Congress, July 4-6, Gold Coast, Australia</i>
June 2019	Tumor acidity and patient alkalization as a novel anticancer strategy	<i>ANZCVS Science Week Congress, July 4-6, Gold Coast, Australia</i>
June 2019	Electrochemotherapy in horses	<i>ANZCVS Science Week Congress, July 4-6, Gold Coast, Australia</i>
July 2021	The role of metronomic chemotherapy in multimodal cancer treatment	<i>2021 ECVS 30th Annual Scientific Meeting (online) 8-10 July 2021</i>
July 2021	The role of electrochemotherapy in multimodal cancer treatment	<i>2021 ECVS 30th Annual Scientific Meeting (online) 8-10 July 2021</i>

September 2022	Electroporation in veterinary medicine: general concepts	<i>Master Unisvet, 26 September 2022 Padova, Italy</i>
September 2022	Clinical applications of electroporation in veterinary medicine: riding the electric waveform	<i>Master Unisvet, 26 September 2022 Padova, Italy</i>
September 2022	Electrochemotherapy in veterinary medicine: clinical cases	<i>Master Unisvet, 26 September 2022 Padova, Italy</i>

CAPACITÀ E COMPETENZE

PERSONALI

Acquisite nel corso della vita e della carriera ma non necessariamente riconosciute da certificati e diplomi ufficiali.

PRIMA LINGUA **ITALIANO**

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

INGLESE

ECCELLENTE

ECCELLENTE

ECCELLENTE

CAPACITÀ E COMPETENZE
RELAZIONALI

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE
ORGANIZZATIVE

[Descrivere tali competenze e indicare dove sono state acquisite.]

CAPACITÀ E COMPETENZE
TECNICHE

[Descrivere tali competenze e indicare dove sono state acquisite.]

PATENTE O PATENTI

ALLEGATI

[Se del caso, enumerare gli allegati al CV.]

Il sottoscritto è a conoscenza che, ai sensi dell'art. 26 della legge 15/68, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003 per le finalità di cui al presente avviso di candidatura.

Data 07-10-2022

Firma

